class=”sc-cffd1e67-0 fmXrkB”>
Swissmedic announced on Thursday that the step was taken ‘after careful investigation’. Beyfortus from the pharmaceutical company Sanofi-Aventis is used as prophylaxis. Pediatricians and children’s hospitals in particular were waiting for approval.
RS viruses cause many colds in autumn and winter. In newborns and young children, they can lead to pneumonia and hospital admissions. After the corona pandemic subsided, serious respiratory diseases increased significantly again in many countries.
According to the pharmaceutical company GSK, the virus causes more than 270,000 hospitalizations and 20,000 deaths in hospitals in Europe every year among people aged 60 and over.
There is no vaccine against RSV available in Switzerland. The European Commission approved the Arexvy vaccine this summer.
(SDA)
Source:Blick

I am Liam Livingstone and I work in a news website. My main job is to write articles for the 24 Instant News. My specialty is covering politics and current affairs, which I’m passionate about. I have worked in this field for more than 5 years now and it’s been an amazing journey. With each passing day, my knowledge increases as well as my experience of the world we live in today.